Panel to discuss Avid's florbetapir

FDA's Peripheral and Central Nervous System Drugs Advisory Committee will meet on Jan. 20 to discuss an NDA from Avid Radiopharmaceuticals Inc. (Philadelphia, Pa.) for florbetapir for use in PET imaging of beta amyloid aggregates in the brain to help rule out Alzheimer's disease (AD). The PDUFA date is not disclosed. Florbetapir is an imaging agent labeled with fluorine 18 (F-18) that binds to amyloid plaques. Eli Lilly and Co. (NYSE:LLY) is acquiring Avid. ...